Joshua S. Savage
Birmingham, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1.
Journal: Journal for immunotherapy of cancer
Published: December 01, 2025
Quantifying UK coastal flood exposure under future sea-level rise to 2300.
Journal: Nature communications
Published: September 11, 2025
Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trial.
Journal: BMC cancer
Published: January 08, 2025
A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer.
Journal: NPJ precision oncology
Published: July 30, 2024
Results and lessons learnt from the WISTERIA phase I trial combining AZD1775 with cisplatin pre- or post-operatively in head and neck cancer.
Journal: BJC reports
Published: September 26, 2023
Protocol for the Tessa Jowell BRAIN MATRIX Platform Study.
Journal: BMJ open
Published: November 15, 2022
Subgroup analyses in randomized controlled trials frequently categorized continuous subgroup information.
Journal: Journal of clinical epidemiology
Published: March 29, 2022
Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial.
Journal: BMJ open
Published: March 05, 2022
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units.
Journal: Trials
Published: January 10, 2022
Last Updated: 09/26/2026